Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
Public ClinicalTrials.gov record NCT02431312. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients
Study identification
- NCT ID
- NCT02431312
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Inovio Pharmaceuticals
- Industry
- Enrollment
- 90 participants
Conditions and interventions
Conditions
Interventions
- INO-1800 Biological
- INO-9112 Biological
- Nucleos(t)ide Analogue Treatment Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 11, 2015
- Primary completion
- May 21, 2018
- Completion
- May 21, 2018
- Last update posted
- Oct 14, 2019
2015 – 2018
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research and Education, Inc. | San Diego | California | 92105 | — |
| University of Miami Schiff Center for Liver Disease | Miami | Florida | 33136 | — |
| Northwell Health | Manhasset | New York | 11030 | — |
| Mount Sinai - PRIME | New York | New York | 10029 | — |
| UC Physicians Company, LLC/Division of Digestive Diseases | Cincinnati | Ohio | 45267 | — |
| Philadelphia VA Medical Center | Philadelphia | Pennsylvania | 19104 | — |
| Harbourview Medical Center | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 15 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02431312, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 14, 2019 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02431312 live on ClinicalTrials.gov.